A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease Save

Date Added
July 9th, 2019
PRO Number
Pro00088643
Researcher
Brenda Hoffman

List of Studies


Profiles_link
Keywords
Crohn's Disease
Summary

Study M16-006 is a randomized, double blind, placebo-controlled 12-week induction study for those subjects with Moderately to Severely Active Crohn's Disease.
This study will evaluate two IV doses of Risankizumab (600 mg and 1200 mg). The selection of the doses in this study was selected by the data provided from the phase II study that was completed previously. The results from the Phase 2 study suggest a potential for increased benefit with 1200 mg administration.

Institution
MUSC
Recruitment Contact
Megan Bickford
843-876-8439
forstere@musc.edu

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment Save

Date Added
July 9th, 2019
PRO Number
Pro00088554
Researcher
Brenda Hoffman

List of Studies


Profiles_link
Keywords
Crohn's Disease
Summary

Study M15-991 is a randomized, double blind, placebo-controlled 12-week induction study. This study is for those subjects with moderately to severely Active Crohn's Disease Who Failed Prior Biologic Treatment.
This study will evaluate two IV doses of Risankizumab (600 mg and 1200 mg). The selection of the doses in this study was selected by the data provided from the phase II study that was completed previously. The results from the Phase 2 study suggest a potential for increased benefit with 1200 mg administration.

Institution
MUSC
Recruitment Contact
Megan Bickford
843-876-8439
forstere@musc.edu

Change_preferences

-- OR --

Create_login